<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841136</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-SCLC-001</org_study_id>
    <nct_id>NCT03841136</nct_id>
  </id_info>
  <brief_title>Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer</brief_title>
  <official_title>Phase II Clinical Trial of Anlotinib Combined With Etoposide and Platinum in the Treatment of Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the progression free survival of patients with extensive stage small cell lung
      cancer treated with anlotinib combined with EP/CE regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the progression free survival of patients with extensive stage small cell lung
      cancer treated with anlotinib combined with EP/CE regimen To evaluate the safety,
      tolerability, overall survival (OS), objective response rate (ORR), disease control rate
      (DCR), and quality of life (QoL) of patients with extensive stage small cell lung cancer
      treated with anlotinib
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
    <description>the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>anlotinib combined with EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anlotinib combined with etoposide and platinum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anlotinib</intervention_name>
    <description>anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1~D3</description>
    <arm_group_label>anlotinib combined with EP</arm_group_label>
    <other_name>etoposide and platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients volunteered to participate in the study and have signed the informed consent.

          2. Histological or cytological diagnosis of extensive small cell lung cancer, and no
             indication of radical surgery or radiotherapy.

          3. There are measurable lesions defined by RECIST standard v1.1. A lesion can be
             considered measurable only if the previously irradiated lesion has clear progression
             after radiotherapy and the previous irradiated lesion is not the sole lesion.

          4. Initially treated patients who have not received any systematic therapy before. If
             have received postoperative adjuvant chemotherapy, the time to relapse is at least 6
             months from the last adjuvant chemotherapy.

        5）18~75 years old; ECOG PS score: 0~1 points; expected survival time is more than 3 months.

        6）The main organs's function meets the following criteria within 14 days before treatment:

          1. Routine blood test (without blood transfusion within 14 days): a) Hemoglobin (HB) ≥ 90
             g / L; b) Absolute neutrophil (ANC) ≥ 1.5 × 109 / L; c) Platelets (PLT) ≥ 80×109/L

          2. Biochemical examination: a) Total bilirubin (TBIL) ≤ 1.5 times of the upper limit of
             the normal (ULN); b) Alanine aminotransferase (ALT) and aspartate aminotransferase AST
             ≤ 2.5ULN.To patients with liver metastasis, ALT and AST ≤ 5ULN; c) Serum creatinine
             (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min;

          3. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ the lower
             limit of the normal (50%).

        7）Patients with previously treated asymptomatic CNS metastases are allowed to participate
        in this study if all of the following criteria are met: a) No need for continuous
        corticosteroid therapy for CNS disease; b) No radiotherapy within 7 days prior to
        enrollment treatment; c) Imaging examination from the end of radiotherapy to screening
        period shows no CNS progression.

        8）Women of childbearing age should agree to conduct contraception (such as intrauterine
        devices, contraceptives or condoms) during the study and within 6 months after the end of
        the study; and the serum or urine pregnancy test is negative within 7 days prior to study
        enrollment and they must be non-lactating patients; Men should agree to conduct
        contraception during the study and within 6 months after the end of the study.

        Exclusion Criteria:

          1. Patients who have been treated with anlotinib capsules in the past.

          2. Patients who have previously received systemic chemotherapy, signal transduction
             inhibitors, targeted therapies, hormone and endocrine therapy.

          3. Patients with other malignant tumors occurred within 5 years prior to the enrollment,
             except those with cured cervical carcinoma in situ and superficial bladder tumors [Ta
             (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement
             membrane)] , basal or squamous cell skin cancer, and localized prostate cancer and
             ductal breast carcinoma in situ treated with radical surgery.

          4. Unresolved toxicity due to any previous treatment above CTC AE (4.0) level 2 or
             higher, excluding hair loss.

          5. Patients with a variety of factors affecting oral medications (such as dyspahgia,
             gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.)

          6. Patients with symptomatic CNS metastases.

          7. Patients with dysfucitonal coagulation (PT&gt;16s, APTT&gt;43s, TT&gt;21s, Fbg&lt;2g/L), and
             bleeding tendency (the following condition must be met within 14 days before the
             enrollment: the INR is within the normal range without using anticoagulants); Patients
             treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or the
             like; Patients with International Normalized Ratio (INR) of less than1.5 are allowed
             to use low-dose warfarin (1 mg orally, once daily) or aspirin (with a daily dose of no
             more than 100 mg) for prophylactic purposes.

          8. Patients with major surgical treatment, incisional biopsy or tremendous traumatic
             injury within 28 days prior to the enrollment.

          9. Patients with tumors that have invaded tissues surrounding vital blood vessels founded
             in imaging or with a high probability of fatal bleeding due to the invasion of tumors
             to vital blood vessels according to the judgements of the researchers during the
             follow-up study.

         10. Patients with uncontrolled pleural, pericardial, or peritoneal effusion requiring
             repeated drainage.

         11. Patients with any severe and/or uncontrolled disease, including:

               1. Patients with unsatisfactory blood pressure control (systolic blood pressure &gt;150
                  mmHg, diastolic blood pressure &gt;90 mmHg).

               2. Patients with myocardial ischemia or myocardial infarction of Grade I of higher
                  level, arrhythmia (including QTC ≥ 440ms) and congestive heart failure above
                  Grade 2 (New York Heart Association (NYHA) classification).

               3. Patients with active or uncontrolled severe infection (≥ CTC AE Level 2).

               4. Patients with a history of immunodeficiency, including HIV-positive or other
                  acquired, congenital immunodeficiency disease, or a history of organ
                  transplantation.

               5. Patients with poor control of diabetes (fasting blood glucose (FBG)&gt;10mmol/L).

               6. Patients with urine protein ≥ ++ indicated by routine urine test, and confirmed
                  24-hour urine protein quantitation &gt; 1.0 g.

               7. Patients with seizures requiring treatment.

         12. Patients with bleeding tendency or medical history regardless of severity; Patients
             undergone bleeding events of a level ≥ CTCAE 3 within 4 weeks prior to the enrollment,
             and with unhealed wounds, ulcers or fractures.

         13. Patients undergone venous thrombosis events currently or within 6 months, such as
             cerebrovascular accidents (including transient ischemic attacks), deep vein
             thrombosis, and pulmonary embolism.

         14. Patients with a history of psychotropic drug abuse from which they are unable to
             abstain or with mental disorders.

         15. Patients who have participated in other clinical trials of anti-tumor drugs within
             four weeks.

         16. Patients with severe disease that threaten the safety of themselves or affect the
             completion of the study according to the investigators' judgment.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wang jia lei, doctor</last_name>
    <phone>18017312369</phone>
    <email>haitunqiao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang jia lei, PD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jialei Wang</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

